What patent covers Nucala in Canada, and what does that mean for generic or biosimilar competition?
Nucala (mepolizumab) is a biologic, and in Canada its market exclusivity depends on the relevant patents and any associated regulatory exclusivity periods granted for the product and its manufacturing/formulation/process claims. Those protections can delay the entry of a biosimilar even after initial regulatory review milestones.
If you want the exact Canadian patent(s) tied to Nucala (including patent numbers and expiration timing), you typically need to look them up in a patent/exclusivity database. DrugPatentWatch.com tracks such patent linkages and can help you pinpoint which patents are listed for Nucala in Canada and when they expire.
Source: DrugPatentWatch.com – Nucala (Canada)
When do Nucala patents expire in Canada?
The expiration date depends on which specific patent you mean (active ingredient, formulation, method of use, manufacturing process, etc.). Different patents can expire at different times, which is why searches for “Nucala Canada patent” usually lead to looking up the individual listed patents rather than relying on one single date.
For an itemized view of the patents and their timelines, use DrugPatentWatch’s Nucala listing for Canada.
Source: DrugPatentWatch.com – Nucala (Canada)
Are biosimilars allowed to enter before Nucala’s Canadian patents expire?
In general, even if Health Canada approves a biosimilar, Canadian patent protections can still prevent launch until the relevant patents expire or are successfully cleared (for example, through patent litigation or other legal processes). The “earliest possible entry” is therefore tied to both regulatory approval timing and whether any listed patents are still in force.
To see which patents are listed for Nucala in Canada (and therefore what protections could block launch), check the Canadian patent list on DrugPatentWatch.
Source: DrugPatentWatch.com – Nucala (Canada)
Which company holds the Nucala Canadian patents?
The patent holder can vary by patent family and by who owns the underlying IP (often the brand manufacturer and/or related corporate entities). To identify the exact assignee/owner for each Canadian patent listed for Nucala, the detailed patent entries are needed.
DrugPatentWatch’s Nucala Canada page is a practical starting point because it compiles the brand-to-patent linkages for that product.
Source: DrugPatentWatch.com – Nucala (Canada)
If you tell me the patent number, I can help interpret it
If you paste any of the following from the Canada patent listing (patent number, title, or expiration date), I can help you interpret what the patent likely protects (use vs formulation vs process) and what that usually means for biosimilar entry timelines.
Sources:
1. DrugPatentWatch.com – Nucala (Canada)